GLP-1 Agonists: Uses, Mechanism, and Side Effects
https://my.clevelandclinic.org/health/treatments/13901-glp-1-agonists The provided text from the Cleveland Clinic offers a comprehensive overview of GLP-1 agonists, a class of medications primarily used to manage Type 2 diabetes and obesity. It explains how these injectable drugs mimic a natural hormone to regulate blood sugar, slow digestion, and increase feelings of fullness, leading to potential weight loss. The source lists various approved GLP-1 agonists and their typical administration frequencies, […]
Orforglipron for Early Type 2 Diabetes Management
This scientific paper presents the ACHIEVE-1 trial, a phase 3 study investigating orforglipron, an oral, nonpeptide GLP-1 receptor agonist, for treating type 2 diabetes. The research evaluates its efficacy and safety as a once-daily monotherapy in adults whose type 2 diabetes is managed solely through diet and exercise. The findings demonstrate that orforglipron significantly reduces glycated hemoglobin levels and promotes body weight reduction over […]
Novo is not dead yet! Novo Nordisk’s experimental drug results in up to 24% weight loss
June 20 (Reuters) – Novo Nordisk (NOVOb.CO) On Friday said full results from early-stage trials show that its experimental drug, amycretin, helped overweight and obese adults lose up to 24% of their weight as the Danish company readies for late-stage studies to start next year. The company said side effects of the drug, tested as both a […]
ADA (American Diabetes Association) June 20-23 Obesity Medicines – Other Posters and Talks
🧪 NA‑931 (Bioglutide™) – Biomed Industries, Inc.Presentation (Oral):Title: “Phase 2 Clinical Trials of NA‑931, an Oral Novel Quadruple IGF‑1, GLP‑1, GIP, and Glucagon Receptor Agonist, Reduces Body Weight Without Muscle Loss.”Presenter: Dr. Lloyd L. Tran (CEO)Date & Time: June 20, 2025 – oral session (specific time TBD at conference)Poster:Title: “Association Between Alzheimer’s Disease (AD) and Obesity: Clinical Trial […]
ADA (American Diabetes Association) June 20-24 Obesity Medicines – Lilly Posters and Talks
Lilly Orgorglipron Orforglipron is a novel, oral, non-peptide GLP‑1 receptor agonist, and the ACHIEVE‑1 Phase III data demonstrated efficacy and tolerability comparable to existing injectables Oral Presentation – Lilly will feature its oral GLP‑1 candidate, orforglipron, with topline results from its Phase III ACHIEVE‑1 trial showing positive safety, glycemic control, and weight loss (~8 % at 40 weeks). This […]
ADA (American Diabetes Association) June 20-23 Obesity Medicines Novo Nordisk Posters and Talks
Novo CagriSema CagriSema is an investigational medication being developed by Novo Nordisk for the treatment of obesity and type 2 diabetes. It is a fixed-dose combination of two drugs: Cagrilintide: An amylin analog that helps regulate appetite and reduce food intake Semaglutide: A glucagon-like peptide-1 (GLP-1) receptor agonist that improves blood sugar control and promotes weight loss. CagriSema is designed […]
Tirzepatide for Weight Loss in Non-Diabetics: A Meta-Analysis
Kommu S, Sharma PP, Gabor RM. Efficacy and Safety of Tirzepatide on Weight Loss in Patients Without Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Obes Rev. 2025 Jun 13:e13961. doi: 10.1111/obr.13961. Epub ahead of print. PMID: 40510020. This article presents a systematic review and meta-analysis on the efficacy and safety of tirzepatide for weight loss in […]
Wikipedia and the Weight Loss Drugs
Wikipedia is a free, multilingual, web-based, and openly editable encyclopedia maintained by a global community of volunteers. It’s hosted by the non-profit Wikimedia Foundation. Wikipedia offers articles on various topics, ranging from celebrities and science to history and culture. It’s considered one of the most popular websites on the internet. There is a large amount of information on obesity, GLP-1s, […]
Defining Clinical Obesity
Definition and diagnostic criteria of clinical obesityRubino, Francesco et al.The Lancet Diabetes & Endocrinology, Volume 13, Issue 3, 221 – 262 The Lancet Diabetes & Endocrinology Commission’s comprehensive work on defining and diagnosing clinical obesity, distinguishing it from mere excess adiposity. A large international expert group, including patient representatives, utilized a Delphi-like consensus process to establish objective criteria for clinical obesity in […]
ClinicalTrials.gov – Who, what, when, and where.
ClinicalTrials.gov is a public database maintained by the U.S. National Library of Medicine (NLM) at the National Institutes of Health (NIH). It provides detailed information about clinical studies involving human participants, conducted worldwide. Key Features:Registry: Researchers and sponsors (such as pharmaceutical companies, academic institutions, and government agencies) are required or encouraged to register their clinical […]